Genomictree Inc. (228760.KQ) stock: key figures, P/E, revenue and dividend

Energy · Coal & Consumable Fuels · South Korea · ISIN KR7228760005

Price
9,920.00 KRW
Market cap
243.30 bn KRW
P/E (2025)
–
P/S (2025)
64.71
Dividend yield
0.00 %
Net margin
-238.98 %
Return on equity (ROE)
-7.81 %
Return on assets (ROA)
-7.44 %

Genomictree Inc. financials

Fiscal year20242025
Revenue2.36 bn KRW3.76 bn KRW
Gross profit-726.56 m KRW713.90 m KRW
Operating income-15.31 bn KRW-11.30 bn KRW
EBIT-10.09 bn KRW-8.78 bn KRW
Net income-10.24 bn KRW-8.99 bn KRW
Diluted EPS – continuing operations-426.94 KRW-366.37 KRW

Full history since 2018, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Genomictree Inc.

Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect B for detection of genetic and epigenetic markers associated with bladder cancer in hematuria patients. It also provides AccuraDTect SARS-CoV-2 RT-qPCR kits, test providers, and nucleic acid transport medium products. The company was founded in 2000 and is headquartered in Daejeon, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.